Cited 0 times in
Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 김중선 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 유승찬 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 이용준 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 이상협 | - |
dc.contributor.author | 이용호 | - |
dc.date.accessioned | 2024-03-22T07:00:33Z | - |
dc.date.available | 2024-03-22T07:00:33Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198668 | - |
dc.description.abstract | Aim: This study evaluated the safety and efficacy of a moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome (MetS) and atherosclerotic cardiovascular disease. Materials and methods: In this post-hoc subgroup analysis of the RACING trial, patients were analysed based on the presence of MetS. MetS was defined as meeting at least three of the five following criteria: (a) elevated waist circumference; (b) elevated triglycerides; (c) reduced high-density lipoprotein cholesterol; (d) elevated blood pressure; and (e) elevated fasting glucose. The primary outcome was a 3-year composite of cardiovascular death, major cardiovascular events, or non-fatal stroke. Results: Of the 3780 patients enrolled in the RACING trial, 1703 (45.1%) had MetS at baseline. The primary outcome rate was 10.1% and 10.3% in patients with MetS receiving ezetimibe combination therapy versus high-intensity statin monotherapy (hazard ratio = 0.97; 95% confidence interval = 0.72-1.32; p = .868). Lower rates of intolerance-related drug discontinuation or dose reduction (3.9% vs. 8.0%; p < .001) and lower low-density lipoprotein cholesterol levels (57 vs. 65 mg/dl; p < .001) were observed with ezetimibe combination therapy versus high-intensity statin monotherapy. Furthermore, the rate of new-onset diabetes was 18.5% and 19.1% in each group (p = .822). There were no significant interactions between MetS and therapy regarding study outcomes in the total population. Conclusions: In patients with MetS and atherosclerotic cardiovascular disease, a moderate-intensity statin with ezetimibe combination therapy had comparable cardiovascular benefits with those of high-intensity statin monotherapy. Meanwhile, ezetimibe combination therapy was associated with lower drug intolerance and low-density lipoprotein cholesterol levels, but there was no apparent between-group difference in new-onset diabetes. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Blackwell | - |
dc.relation.isPartOf | DIABETES OBESITY & METABOLISM | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Anticholesteremic Agents* / adverse effects | - |
dc.subject.MESH | Atherosclerosis* / complications | - |
dc.subject.MESH | Atherosclerosis* / drug therapy | - |
dc.subject.MESH | Atherosclerosis* / prevention & control | - |
dc.subject.MESH | Cardiovascular Diseases* / complications | - |
dc.subject.MESH | Cardiovascular Diseases* / epidemiology | - |
dc.subject.MESH | Cholesterol, LDL | - |
dc.subject.MESH | Diabetes Mellitus* / drug therapy | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Ezetimibe / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects | - |
dc.subject.MESH | Metabolic Syndrome* / complications | - |
dc.subject.MESH | Metabolic Syndrome* / drug therapy | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with metabolic syndrome and atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Yong-Joon Lee | - |
dc.contributor.googleauthor | Sang-Hyup Lee | - |
dc.contributor.googleauthor | Seng Chan You | - |
dc.contributor.googleauthor | Yong-Ho Lee | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.identifier.doi | 10.1111/dom.15374 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A02269 | - |
dc.contributor.localId | A02478 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A06392 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A04403 | - |
dc.relation.journalcode | J00722 | - |
dc.identifier.eissn | 1463-1326 | - |
dc.identifier.pmid | 37994242 | - |
dc.identifier.url | https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.15374 | - |
dc.subject.keyword | atherosclerotic cardiovascular disease | - |
dc.subject.keyword | ezetimibe | - |
dc.subject.keyword | metabolic syndrome | - |
dc.subject.keyword | statin | - |
dc.contributor.alternativeName | Ko, Young Guk | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 안철민 | - |
dc.contributor.affiliatedAuthor | 유승찬 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 이용준 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 829 | - |
dc.citation.endPage | 839 | - |
dc.identifier.bibliographicCitation | DIABETES OBESITY & METABOLISM, Vol.26(3) : 829-839, 2024-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.